COVAXIN Phase 1 human trials begin; first dose administered to 30-year-old Delhi resident
Over 3,500 volunteers have registered themselves for the trial at AIIMS this week, of whom the screening of 22 people is underway, doctors said
New Delhi: The phase-I human clinical trial of India's first indigenously-developed vaccine against the novel coronavirus, Covaxin, began at the Delhi AIIMS on Friday with the first dose of the injection given to a man in his 30s.
Already, over 3,500 volunteers have registered themselves for the trial at AIIMS since last Saturday, of whom the screening of at least 22 people is underway, said Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS and the principal investigator of the study.
"The first volunteer, a resident of Delhi, was screened two days ago and all his health parameters were found to be within the normal range. He also does not have any co-morbid conditions.
"The first dose of 0.5 ml intramuscular injection was given to him around 1.30 pm. No immediate side-effects have been observed so far. He was under observation for two hours and will be monitored for the next seven days," Rai said.
Few more participants would be given the vaccine on Saturday after their screening reports come.
AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II randomised, double-blind, placebo-controlled clinical trials of Covaxin.
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
The second phase would include around 750 volunteers from all 12 sites together, Rai said.
Phase I of the vaccine trial will be done on healthy people aged 18-55 years having no co-morbid conditions. Women with no pregnancy will also be selected to be a part of the trial in the first phase.
In the second phase, 750 people will be recruited between 12-65 years, AIIMS Director Dr Randeep Guleria had said.
Already, around 1,800 volunteers have registered themselves for the trial at AIIMS, he had said.
"In the first phase we see the safety of the vaccine which is of primary importance and the dose range is also calculated," he said.
There are three formulations of the vaccine, and each subject will be given any one of the formulation in two doses two weeks apart.The first 50 will get the lowest strength dose of the vaccine. If it is found to be safe in them, then it will be given to another 50 patients in high doses, acording to Rai.
Covid-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
Vaccines play a crucial role in preventing infection, hospitalizations, and adverse outcomes which cause deaths
India logs 17,336 new COVID-19 cases in last 24 hours, up 30% from yesterday; positivity rate jumps to 4.32%
Delhi and Maharashtra reported the maximum number of COVID-19 cases in the last 24 hours. As many as 13 people died of COVID-19, increasing the cumulative casualty due to the virus in the country to 5,24,954
The 81-year-old Fauci, who is fully vaccinated and has received two booster shots, was experiencing mild COVID-19 symptoms. He tested positive on a rapid antigen test